Federal Government Scrutinizing Sales Rep Dealings With Trial Results
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers who let their sales representatives disseminate clinical trial results for unapproved devices or off-label indications are skating on thin ice, according to the Department of Justice and the HHS Office of Inspector General
You may also be interested in...
Medtronic To Track Sales Contacts, Pay $40 Mil. To Settle Kickback Probe
Medtronic will begin recording all transactions between its spine product sales personnel and physicians as part of a settlement agreement with the U.S. Department of Justice
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.